You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 3, 2025

Thailand’s New Cannabis Controls Impact Doctors, Dispensaries, and Growers

Subscribe to Updates

Liberal cannabis access in Thailand is officially over. On June 26, 2025, the Ministry of Public Health brought the inflorescence of cannabis back under tight control through its new Notification on Controlled Herbs (Cannabis) 2025 (“Notification 2025”). The message is that cannabis may stay in the marketplace, but only if strictly supervised under a cannabis prescription from a medical professional. Two main pillars now define compliance: (1) prescription requirements and mandatory reporting, and (2) Good Agricultural and Collection Practices (GACP). This article aims to summarize each essential element for the relevant parties.

1. Getting a Prescription: Digital Diagnosis vs. Real-World Paperwork?

Dispensaries, even those with a license to sell cannabis, can no longer sell cannabis to walk-in customers who don’t have a valid prescription. Sales are lawful only when the buyer duly presents a cannabis prescription issued by one of seven recognized professional practitioners, including medical doctors, Thai traditional medicine doctors, applied Thai traditional medicine doctors, folk healers, Chinese medicine practitioners, pharmacists, or dentists.

Notification 2025 does not mention teleconsultations or online prescriptions. Nonetheless, policymakers at this stage opine that an online chat or casual consultation, with the prescription sent via a social media platform or e-mail, would not comply with this latest regulation. In order to be eligible to issue cannabis prescriptions, medical doctors should be working in a clinic or hospital and should issue paper-based prescriptions. The official prescription form, called a PT 33, must be used. The prescriber has the discretion to indicate the cannabis strain (or product type), dosage, and intended duration of use, which cannot exceed 30 days per prescription. This ensures that the product matches the patient’s medical needs and aligns with professional treatment guidelines. In practice, each prescription will be valid for one-time use only and cannot be refilled; a new prescription will be required for each subsequent use.

Dispensaries must retain every prescription for at least one year and must be able to present the prescriptions immediately upon request for inspection by the Department of Thai Traditional and Alternative Medicine (DTAM) or by a police officer. Because the controlled herbs regime treats cannabis flowers as a potentially divertible psychotropic drug, any lapse in identity verification (e.g., lack of a medical practitioner license number), signature integrity, or recordkeeping can lead to the suspension of the dispensary’s selling license. If a dispensary fails to follow the prescription’s instructions and requirements, the dispensary and its proprietor may be charged with an offense punishable by up to one year’s imprisonment or a THB 20,000 fine.

2. GACP: Shift from “Any Farm Will Do” to Standardized Agricultural Field

Another game-changing requirement is that cannabis flowers sold or exported must originate from a cultivation site certified under Good Agricultural and Collection Practices (GACP). In practical terms, the DTAM inspectors will audit and certify a site by reviewing the soil, water, pesticide use, worker hygiene, and postharvest handling. Certification under GACP is valid for one to three years, with annual surveillance. Growers must keep seed-to-sale records, including seed provenance, fertilizer logs, pest-management reports, harvest dates, and quality-control tests. Without GACP-validated evidence, downstream licenses (for dispensaries and for exporters) are exposed to a possible suspension.

Practical Takeaways

These significant changes to Thailand’s regulatory regime for cannabis have far-reaching implications for various businesses and professionals:

  • Medical professionals and clinics: These parties must understand and use the correct prescription form (PT 33) and keep a copy of the diagnostic evidence, as inspectors are likely to increasingly cross-check medical files against prescription volumes.
  • Dispensaries and budtenders: The role of the budtender is evolving from a retail assistant to a compliance-focused professional. Budtenders must be trained to verify the authenticity of prescriptions and buyers’ personal information, as well as confirming that products have been derived from a GACP field, in order to ensure that the dispensed products match every prescription’s details. They are also responsible for maintaining records and supporting regulatory inspections.
  • Growers: There must be a shift to treat GACP as a full-scale quality-management system, which would mean keeping continuous logs, submitting to internal audits, and participating in annual refresher training to keep updated on the latest regulatory requirements—none of which would be optional practices for a grower hoping to maintain GACP certification.

Future Direction

With Thailand’s tightening of cannabis regulations, many dispensaries in the country are expected to transition into the cannabis clinic business, particularly specializing in traditional Thai medicine. This shift will require additional licensing (i.e., for clinic establishment and clinic operations), the presence of qualified medical professionals, and compliance with the required medical standards. The integration of cannabis into traditional medicine clinics is seen as a sustainable model for the future, aligning with Thailand’s heritage and regulatory goals.

Related Professionals

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

August 20, 2026
As part of its membership in Lex Mundi, Tilleke & Gibbins has released the latest edition of its Guide to Doing Business in Thailand, providing an overview of the legal, regulatory, and commercial considerations for companies establishing or expanding operations in Thailand. The 2026 edition offers practical insight into the country’s business environment, investment framework, and operational requirements. The guide covers a wide range of topics relevant to foreign and domestic investors, including: Investment incentives and promotion schemes Financial facilities and banking regulations Exchange controls and money transfers Import and export regulations Business structures and incorporation options Requirements for establishing a business Operational and compliance considerations Business cessation and insolvency procedures Employment and labor laws Taxation Immigration and visa requirements Prepared by Tilleke & Gibbins lawyers across multiple practice areas, the publication outlines key aspects of doing business in Thailand, including foreign investment restrictions, regulatory compliance obligations, corporate structures, employment requirements, and recent legal and economic developments affecting investors. The publication forms part of Lex Mundi’s Country Guides series, a global collection of jurisdiction-specific reference materials prepared by member firms around the world. Together, these guides help companies evaluate opportunities, compare regulatory environments, and plan international business activities across multiple markets. The full Guide to Doing Business in Thailand 2026 is available through the button below.
Read More
August 10, 2026
On June 17, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 10 of 2026 on Nutritional Information on Processed Food Labels. The new regulation, which revokes three previous nutrition labeling regulations, introduces several notable changes affecting food and beverage manufacturers, importers, and distributors. These changes range from updated nutrient reference values and serving-size requirements to the introduction of the Nutri-Level front-of-pack labeling system for certain beverage products. Businesses operating in Indonesia should carefully review these developments and assess their products’ compliance with the new requirements during the transition period. Implementation of the Nutri-Level Labeling System To implement the recently issued decree on Nutri-Level labeling, BPOM Regulation No. 10 of 2026 stipulates the requirements to implement the Nutri-Level labeling system on the front-of-pack. Under the new framework, ready-to-drink beverages, powdered beverages, and liquid or solid concentrates are required to display Nutri-Level labeling on the front label of their packaging. The Nutri-Level labeling system classifies products into color-coded levels A through D based on their sugar, sodium, and total fat content. The applicable Nutri-Level is determined based on the lowest level measured in the assessment of sugar, sodium, and total fat content. For products classified as level C or D, the Nutri-Level label must be accompanied by information on the relevant sugar, sodium, and total fat content per 100 ml of the ready-to-consume product. Products classified as level A or B may either display only the Nutri-Level designation or display the Nutri-Level together with the relevant nutritional information per 100 ml. Minimum Vitamin and Mineral Content Required for Declaration BPOM Regulation No. 10 of 2026 introduces a stricter threshold for the declaration of vitamins and minerals in the nutritional value information section (ING). Vitamins or minerals may only be declared if they are present at a
Read More
August 10, 2026
The drug registration process in Vietnam will be simplified, particularly for foreign applicants, following the recent issuance by Vietnam’s Ministry of Health (MOH) of a new circular that is expected to reduce administrative hurdles. Circular No. 32/2026/TT-BYT on the registration of drugs and medicinal ingredients (Circular 32) was issued on July 29, 2026, and will take effect on October 1, 2026, replacing Circular No. 12/2025/TT-BYT. Key provisions of the new circular are discussed below. Five-Year Data Exclusivity and Five-Month Public Disclosure Framework Circular 32 updates data protection guidelines by explicitly referencing Article 128 of the amended Intellectual Property Law, which sets out that new drugs supported by clinical trial data submitted for the first time will be granted a five-year data exclusivity period from the date of the initial marketing authorization (MA) approval. Subsequent applications that rely on the originator’s protected data will not be eligible for approval from the date of submission of the originator’s registration dossier until five years after the first MA is granted. Furthermore, in accordance with the new regulations, the regulatory authority must publicly disclose information on subsequent applications five months before the granting of MA, providing originator companies with an opportunity to exercise and enforce their intellectual property rights. Simplified Requirements for Foreign Legal Documents Circular 32 expands the circumstances under which legal documents issued by foreign authorities are exempt from consular legalization and authenticity verification requirements. Specifically, such documents may be exempt if the Drug Administration of Vietnam (DAV) is able to verify their authenticity directly through official electronic means, including written confirmation or email correspondence sent directly to the MOH by the competent foreign authority, or publicly accessible English-language databases maintained by recognized foreign regulatory authorities. In addition, the new circular permits the submission of electronic notarized copies of legal documents
Read More
July 24, 2026
As food innovation continues to accelerate, manufacturers are increasingly introducing ingredients derived from new sources, produced using novel technologies, or lacking a significant history of human consumption. While these innovations create new opportunities for the food industry, they also raise important questions regarding consumer safety. For this reason, many jurisdictions, including Thailand, the European Union, Australia and New Zealand, Canada, and Singapore, require a premarket safety assessment for novel food ingredients before they can be placed on the market. The objective of this assessment is to ensure that each ingredient is safe for its intended use and level of consumption, does not present toxicological, allergenic, microbiological, or nutritional concerns, and will not mislead consumers. Scientific authorities typically evaluate the ingredient’s identity, manufacturing process, composition, specifications, anticipated dietary exposure, toxicological information, nutritional impact, and history of use before determining whether it can be marketed. Against this background, the Thai Food and Drug Administration (FDA) recently took an important step toward improving regulatory transparency by publishing, for the first time, a consolidated public list of substances that have successfully completed the Thai FDA’s safety assessment process, including substances determined to be novel foods and those determined not to fall within the novel food category. The list identifies the approved substances, the corresponding manufacturers or importers, approval dates, and the approved conditions of use. Although the publication does not change the existing legal framework governing novel food approvals, it provides businesses with greater visibility into the Thai FDA’s regulatory precedents and the types of substances that have previously been accepted through the safety assessment process. The full announcement is available on the Thai FDA’s website. As the list is now publicly available, it also provides useful insight into the types of substances that have successfully completed the Thai FDA’s safety assessment process.
Read More